Skip to main content
. Author manuscript; available in PMC: 2021 Oct 24.
Published in final edited form as: Eur Urol. 2018 Oct 29;75(3):523–531. doi: 10.1016/j.eururo.2018.10.025

Table 2 –

Number of patients from each centre in GAP3 at 5 yr of follow-up

Centre Still on AS Still on AS, follow-up <5 yr Lost to follow-up Progression Converted to active treatment Watchful waiting Death from other causes Total
EU-Atlanta 5 41 0 2 0 0 0 48
KB-Baden 44 52 0 22 24 2 1 145
UOF-Calgary 82 346 0 80 30 0 0 538
CUHT-Cambridge 21 162 14 18 7 1 1 224
EMC-Rotterdam 49 18 3 33 4 5 0 112
other PRIAS centres 149 1368 26 392 136 51 13 2135
SU-Gothenburg 293 147 1 111 142 0 43 737
HUCH-Helsinki 58 97 1 97 9 17 3 282
JHU-Baltimore 461 315 91 400 141 0 9 1417
KU-Kagawa 29 2 1 45 19 3 5 104
CHU-Lille 4 94 10 36 10 0 1 155
GSTT-London 58 43 0 83 8 0 2 194
UCL-London 30 230 0 0 10 2 0 272
SUS-Malmö 10 90 1 19 4 1 1 126
MEASCAP-Melbourne 53 114 0 63 3 3 0 236
INT-Milan 102 287 0 245 51 23 2 710
MSKCC-New York 443 344 0 56 190 0 16 1049
YUHS-Seoul 0 33 0 2 1 0 0 36
SGH-Singapore 21 93 0 20 46 0 1 181
UCSF-San Francisco 405 487 0 262 94 0 11 1259
IVO-Valencia 22 149 0 61 21 10 5 268
UBC-Vancouver 0 49 1 14 2 0 2 68
Total 2339 4561 149 2061 952 118 116 10 296

GAP3 = Movember’s Global Action Plan Prostate Cancer Active Surveillance initiative; KCL = King's College London; Erasmus MC = Erasmus Medical Center; MSKCC = Memorial Sloan Kettering Cancer Center; PRIAS = Prostate Cancer Research International Active Surveillance; UCL = University College London; UCSF = University of California, San Francisco. See appendix A for institute abbreviations.